These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23722644)

  • 1. Risk of serious atrial fibrillation and stroke with use of bisphosphonates: evidence from a meta-analysis.
    Sharma A; Chatterjee S; Arbab-Zadeh A; Goyal S; Lichstein E; Ghosh J; Aikat S
    Chest; 2013 Oct; 144(4):1311-1322. PubMed ID: 23722644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of atrial fibrillation with use of oral and intravenous bisphosphonates.
    Sharma A; Einstein AJ; Vallakati A; Arbab-Zadeh A; Walker MD; Mukherjee D; Homel P; Borer JS; Lichstein E
    Am J Cardiol; 2014 Jun; 113(11):1815-21. PubMed ID: 24837258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates and atrial fibrillation: systematic review and meta-analysis.
    Loke YK; Jeevanantham V; Singh S
    Drug Saf; 2009; 32(3):219-28. PubMed ID: 19338379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.
    Mak A; Cheung MW; Ho RC; Cheak AA; Lau CS
    BMC Musculoskelet Disord; 2009 Sep; 10():113. PubMed ID: 19772579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonates and risk of cardiovascular events: a meta-analysis.
    Kim DH; Rogers JR; Fulchino LA; Kim CA; Solomon DH; Kim SC
    PLoS One; 2015; 10(4):e0122646. PubMed ID: 25884398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis.
    Bhuriya R; Singh M; Molnar J; Arora R; Khosla S
    Int J Cardiol; 2010 Jul; 142(3):213-7. PubMed ID: 20051297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis.
    John Camm A
    Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of atrial fibrillation among bisphosphonate users: a multicenter, population-based, Italian study.
    Herrera L; Leal I; Lapi F; Schuemie M; Arcoraci V; Cipriani F; Sessa E; Vaccheri A; Piccinni C; Staniscia T; Vestri A; Di Bari M; Corrao G; Zambon A; Gregori D; Carle F; Sturkenboom M; Mazzaglia G; Trifiro G
    Osteoporos Int; 2015 May; 26(5):1499-506. PubMed ID: 25752621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral bisphosphonates and risk of ischemic stroke: a case-control study.
    Christensen S; Mehnert F; Chapurlat RD; Baron JA; Sørensen HT
    Osteoporos Int; 2011 Jun; 22(6):1773-9. PubMed ID: 20945149
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and stroke associated with intravenous bisphosphonate therapy in older patients with cancer.
    Wilkinson GS; Baillargeon J; Kuo YF; Freeman JL; Goodwin JS
    J Clin Oncol; 2010 Nov; 28(33):4898-905. PubMed ID: 20940190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bisphosphonates and atrial fibrillation: clinical trial data suggest possible link.
    Prescrire Int; 2011 Apr; 20(115):96-7. PubMed ID: 21648212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of bisphosphonates on the risk of atrial fibrillation.
    Howard PA; Barnes BJ; Vacek JL; Chen W; Lai SM
    Am J Cardiovasc Drugs; 2010; 10(6):359-67. PubMed ID: 21090829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bisphosphonates and risk of atrial fibrillation: a meta-analysis.
    Kim SY; Kim MJ; Cadarette SM; Solomon DH
    Arthritis Res Ther; 2010; 12(1):R30. PubMed ID: 20170505
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of bisphosphonate therapies and risk of developing atrial fibrillation.
    Bunch TJ; Anderson JL; May HT; Muhlestein JB; Horne BD; Crandall BG; Weiss JP; Lappé DL; Osborn JS; Day JD
    Am J Cardiol; 2009 Mar; 103(6):824-8. PubMed ID: 19268739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between bisphosphonate use and stroke risk: a meta-analysis.
    Lin SM; Lin JY; Tu YK; Wu CH; Peng CC; Munir KM; Bukhari K; Jaggon K; Fu Y; Loh CH; Huang HK
    Osteoporos Int; 2023 Sep; 34(9):1625-1636. PubMed ID: 37249610
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atrial fibrillation and bisphosphonate therapy.
    Pazianas M; Compston J; Huang CL
    J Bone Miner Res; 2010 Jan; 25(1):2-10. PubMed ID: 20091928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous bisphosphonate therapy and atrial fibrillation/flutter risk in cancer patients: a nationwide cohort study.
    Erichsen R; Christiansen CF; Frøslev T; Jacobsen J; Sørensen HT
    Br J Cancer; 2011 Sep; 105(7):881-3. PubMed ID: 21878939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of bisphosphonate and risk of atrial fibrillation in older women with osteoporosis.
    Rhee CW; Lee J; Oh S; Choi NK; Park BJ
    Osteoporos Int; 2012 Jan; 23(1):247-54. PubMed ID: 21431993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.